Contact this trialFirst, we need to learn more about you.
GABA receptor modulator
SAGE-217 for Depression
Recruiting2 awardsPhase 3
Bellevue, Washington
This trial will study the safety and effectiveness of a new drug, SAGE-217, for people with major depressive disorder.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.